Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 3/20 | 0.59 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.59 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14292926 | 0.82 | PDK2 (0.40) | PDK2PDK4MAP4K1CYP19A1 | |
| SCHEMBL3942114 | 0.82 | PDK2 (0.62) | PDK2PDK4 | |
| SCHEMBL4412776 | 0.81 | PDK2 (0.65) | PDK2PDK4 | |
| SCHEMBL4414051 | 0.79 | PDK2 (0.62) | PDK2PDK4PDK1 | |
| SCHEMBL4414582 | 0.78 | PDK2 (0.58) | PDK2PDK4 | |
| SCHEMBL4422582 | 0.77 | PDK2 (0.59) | PDK2PDK4 | |
| SCHEMBL4428321 | 0.75 | PDK2 (0.57) | PDK2PDK4 | |
| SCHEMBL1398187 | 0.73 | CYP1A2 (0.46) | — | |
| SCHEMBL3942987 | 0.72 | PDK2 (0.51) | PDK2PDK4CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3942991 | 0.72 | PDK2 (0.51) | PDK2PDK4CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326229-A1 | ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326229-A1 | ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF | XDH, F7, CYP4X1 | PDK2 178/4885PDK4 212/4885MAP4K1 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.